This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET/CT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.
Age ≥19 years
Diagnosed with PA per 2016 Endocrine Society guidelines
Underwent adrenal CT
Signed informed consent
Women who are pregnant, breastfeeding, or may become pregnant
Individuals who refuse to undergo surgery
Individuals for whom 68Ga-Pentixafor PET/CT, 11C-Metomidate PET/CT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions
Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET/CT
Seoul National University Hospital
Lead sponsor
Samsung Medical Center
Collaborator